Sunday 11 October 2026 Export all BMY data to Excel Powerpack

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.12 0.46 −0.77%
Market cap
$121.7B
P/E
13.0×
Fwd P/E
11.2×
Dividend yield
4.26%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
46.63% 38.75% 40.43% 33.74%

+8 more TTM periods

Piotroski F-Score
7 7 8 7
ROA
10.18% 8.13% 7.72% 6.34%
ROIC
13.69% 11.09% 11.01% 9.83%
Return on Tangible Assets
52.41% 46.31% 52.19% 40.69%
Average Days of Receivables
78.31 70.53 86.44 86.79
Free Cash Flow per Share
5.60 5.84 6.32 7.52
Free Cash Flow
11,440.00 11,908.00 12,845.00 15,302.00
Capital Expenditures
(1,342.00) (1,398.00) (1,311.00) (1,319.00)
Other line items
Cash ROIC
14.95% 15.87% 17.29% 18.20%
Accounts Receivable Turnover
4.48 4.81 4.35 4.28
Accounts Payable Turnover
3.06 3.48 3.88 3.78
Inventory Turnover
5.36 5.28 5.31 4.81
Average Days of Payables
103.40 107.89 93.63 106.82
Days of Inventory on Hand
68.06 70.23 70.45 68.71
Tax Rate
(0.22) (0.24) (0.24) (0.25)
Research and Development Expense of Revenue
21.80% 21.33% 20.65% 21.98%
Selling, General and Administrative Expense of Revenue
15.07% 15.06% 15.08% 15.04%
Share Based Compensation of Revenue
1.12% 1.14% 1.15% 1.12%
Operating CF/Net income
1.38 1.83 2.01 2.75
Depreciation/Fixed assets
0.41 0.47 0.53 0.67
Capex/Depreciation
(0.42) (0.39) (0.33) (0.27)
Revenue per Share
24.09 23.79 23.69 23.59
Operating CF per Share
6.26 6.53 6.96 8.16
Capex per Share
(0.66) (0.69) (0.64) (0.65)
Capex to Sales
0.03 0.03 0.03 0.03

Fold the line items

Columns are period end dates